Related Research Articles
The international nonproprietary name (INN) is an official generic and non-proprietary name given to a pharmaceutical drug or an active ingredient. INNs make communication more precise by providing a unique standard name for each active ingredient, to avoid prescribing errors. The INN system has been coordinated by the World Health Organization (WHO) since 1953.
Bradanicline is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. Phase I clinical trials were completed successfully, and it was in phase II trials.
Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs. In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are the International Nonproprietary Names (INNs); and trade names, which are brand names. Generic names for drugs are nowadays constructed out of affixes and stems that classify the drugs into different categories and also separate drugs within categories. A marketed drug might also have a company code or compound code.
Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator.
Perakizumab (INN) is a humanized monoclonal antibody designed for the treatment of arthritis. It binds to IL17A and acts as an immunomodulator.
Abrilumab is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.
Emibetuzumab (INN) (LY2875358) is a humanized monoclonal antibody designed for the treatment of cancer. It is in phase II trials for patients with NSCLC
Fletikumab (NNC0109-0012) (INN) is a monoclonal antibody designed for the treatment of rheumatoid arthritis.
Lifastuzumab vedotin is a monoclonal antibody designed for the treatment of cancer.
Ulocuplumab is a monoclonal antibody designed for the treatment of hematologic malignancies.
Pinatuzumab vedotin is a monoclonal antibody designed for the treatment of B-cell malignancies.
Seribantumab is a monoclonal antibody designed for the treatment of cancer.
Brontictuzumab is a humanized monoclonal antibody designed for the treatment of cancer.
Lumretuzumab is a humanized monoclonal antibody designed for the treatment of cancer.
Brazikumab is a human monoclonal antibody designed for the treatment of Crohn's disease.
Duvortuxizumab (INN) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies.
Letolizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.
Bleselumab is a human monoclonal antibody designed for the prevention of organ transplant rejection.
Carotuximab (INN) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.
References
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |